Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781128 | 0.86 | CDC25A (0.49) | EIF4ECYP1A1CYP1B1CYP19A1RAB9A | |
| SCHEMBL3816057 | 0.83 | TSHR (0.48) | SCN9ACYP19A1RAB9ANPC1AXL | |
| SCHEMBL3814224 | 0.83 | CYP19A1 (0.52) | EIF4ECYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL6649829 | 0.83 | EIF4E (0.50) | EIF4ECYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL6651011 | 0.80 | EIF4E (0.48) | EIF4ECYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL3816204 | 0.79 | KDM4E (0.49) | EIF4ESCN9ACYP19A1RAB9ANPC1 | |
| SCHEMBL1858562 | 0.78 | EIF4E (0.61) | EIF4ECYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL3819181 | 0.76 | HTT (0.56) | RAB9ANPC1SLC22A12SYK | |
| SCHEMBL3822110 | 0.76 | NPC1 (0.54) | RAB9ANPC1KDM4ETDP1SYK | |
| Hydrochloric Acid SCHEMBL5732896 | 0.75 | NPC1 (0.53) | RAB9ANPC1KDM4ETDP1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | EIF4E 4642/4885CYP1A1 60/4885CYP1A2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.